Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B

PR Newswire
December 27, 2021 — 18:45 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: Beijing biotech Casino China Covid-19 healthcare Hong Kong JD finance Macau medicine taiwan United States Vaccine

Related News:

BICV’s Debut at CES 2025: Showcasing Full-Stack, All-Domain Products on the International Stage

January 9, 2025 — 22:03

JSAUX Debuts at CES 2025, Showcases Innovative FlipGo Portable Monitor

January 5, 2025 — 12:00

Evolving Global Asset Management Industry in Focus at Asset Abu Dhabi

December 11, 2024 — 02:10

Crystal clear: Pingcheng period glassware of Northern Wei Dynasty

November 9, 2024 — 08:00

Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

November 8, 2024 — 17:45

LPS Launches NeuroNode: Empowering Advanced AI for Enterprises with On-Premises LLM

November 7, 2024 — 17:39

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

September 14, 2024 — 08:18

Desay Battery Highlights Advanced Energy Solutions at RE+ 2024

September 11, 2024 — 03:00

Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results

August 29, 2024 — 14:31

Franchising and Licensing Asia (FLAsia) 2024